FOLD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

179.76M

+20.08%

0.069

+37.14%

162.32M

+29.6%

0.028

-140%

181.58M

+17.38%

0.062

-177.5%

Estimates Revision

The market is revising Upward the revenue expectations for Amicus Therapeutics, Inc. (FOLD) for FY2025, with the revenue forecasts being adjusted by 0.4% over the past three months. During the same period, the stock price has changed by 72.05%.

Revenue Estimates for FY2025

Revise Upward

+0.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-68.39%

In Past 3 Month

Stock Price

Go Up

+72.05%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 15.88 USD with a low forecast of 11.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

11.00

Averages

15.88

High

21.00

Current: 0.000

Low

11.00

Averages

15.88

High

21.00

Citi

Samantha Semenkow

Buy

initiated

$17

2025-12-17

Reason

Citi

Samantha Semenkow

Price Target

$17

2025-12-17

initiated

Buy

Reason

Citi analyst Samantha Semenkow initiated coverage of Amicus with a Buy rating and $17 price target. The company is focused on commercializing rare disease therapies, the analyst tells investors in a research note. The firm believes Galafold and PomOp are positioned for combined sales of over $1B in 2028.

JPMorgan

NULL -> Overweight

maintain

$18 -> $19

2025-11-06

Reason

JPMorgan

Price Target

$18 -> $19

2025-11-06

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Amicus to $19 from $18 and keeps an Overweight rating on the shares. The firm updated the company's model.

Goldman Sachs

Neutral

maintain

$9 -> $11

2025-11-05

Reason

Goldman Sachs

Price Target

$9 -> $11

2025-11-05

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Amicus to $11 from $9 and keeps a Neutral rating on the shares. Amicus reported Q3 revenue in line with estimates, and Goldman Sachs is encouraged by continued commercial execution per positive GAAP net income in Q3, which should be sustained from here, and management's confidence in achieving FY25 consensus revenue, the analyst tells investors in a research note.

Needham

Hold

Buy

upgrade

$14

2025-09-18

Reason

Needham

Price Target

$14

2025-09-18

upgrade

Hold

Buy

Reason

Needham upgraded Amicus to Buy from Hold with a $14 price target.

Needham

Hold

Buy

upgrade

$14

2025-09-18

Reason

Needham

Price Target

$14

2025-09-18

upgrade

Hold

Buy

Reason

Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target. The FDA's decision to no longer require a panel meeting for Travere's (TXTX) Filspari, coupled with last year's Parasol recommendation and Dimerix's prior Type C meeting with the FDA, indicate reduction in proteinuria is a suitable primary endpoint for full approval in focal segmental glomerulosclerosis, the analyst tells investors in a research note. The firm believes this lowers the regulatory risk for Amicus' DMX-200. Despite DMX-200 being a Phase III program with peak sales potential of over $1.5B in the U.S., Amicus' opportunity in FSGS is not priced into the stock, contends Needham.

JPMorgan

NULL -> Overweight

maintain

$16 -> $18

2025-08-03

Reason

JPMorgan

Price Target

$16 -> $18

2025-08-03

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Amicus to $18 from $16 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect a December 2026 target versus 2025 previously.

Valuation Metrics

The current forward P/E ratio for Amicus Therapeutics Inc (FOLD.O) is 59.81, compared to its 5-year average forward P/E of 4.88. For a more detailed relative valuation and DCF analysis to assess Amicus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

4.88

Current PE

59.81

Overvalued PE

128.60

Undervalued PE

-118.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

41.54

Current EV/EBITDA

37.76

Overvalued EV/EBITDA

187.40

Undervalued EV/EBITDA

-104.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.86

Current PS

6.13

Overvalued PS

9.26

Undervalued PS

4.46

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FOLD News & Events

Events Timeline

No data

News

7.0

01-08PRnewswire

Halper Sadeh Investigates TreeHouse Foods' $22.50 Share Sale to Industrial F&B Investments

2.0

01-08NASDAQ.COM

Exelixis Collaborates with Natera for STELLAR-316 CRC Study

7.0

01-07Globenewswire

Halper Sadeh Investigates EKSO Merger and Other Transactions

People Also Watch

Frequently Asked Questions

What is Amicus Therapeutics Inc (FOLD) stock price today?

The current price of FOLD is 14.28 USD — it has increased 0 % in the last trading day.

What is Amicus Therapeutics Inc (FOLD)'s business?

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

What is the price predicton of FOLD Stock?

What is Amicus Therapeutics Inc (FOLD)'s revenue for the last quarter?

Amicus Therapeutics Inc revenue for the last quarter amounts to 169.06M USD, increased 19.46 % YoY.

What is Amicus Therapeutics Inc (FOLD)'s earnings per share (EPS) for the last quarter?

Amicus Therapeutics Inc. EPS for the last quarter amounts to 0.06 USD, decreased -400.00 % YoY.

What changes have occurred in the market's expectations for Amicus Therapeutics Inc (FOLD)'s fundamentals?

How many employees does Amicus Therapeutics Inc (FOLD). have?

Amicus Therapeutics Inc (FOLD) has 499 emplpoyees as of January 10 2026.

What is Amicus Therapeutics Inc (FOLD) market cap?

Today FOLD has the market capitalization of 4.42B USD.